Impact of Dyslipidemia on the Risk of Second Cancer in Thyroid Cancer Patients: A Korean National Cohort Study (original) (raw)

• Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013;45(1):1–14.
  Article CAS PubMed PubMed Central Google Scholar
• Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–7.
  Article CAS PubMed Google Scholar
• Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control. 2009;20(5):525–31.
  Article PubMed Google Scholar
• Colonna M, Grosclaude P, Remontet L, et al. Incidence of thyroid cancer in adults recorded by French cancer registries (1978–1997). Eur J Cancer. 2002;38(13):1762–8.
  Article CAS PubMed Google Scholar
• Burgess JR. Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982–1997). Thyroid. 2002;12(2):141–9.
  Article PubMed Google Scholar
• Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br J Cancer. 2001;85(9):1335–9.
  Article CAS PubMed PubMed Central Google Scholar
• Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH. Prediction of cancer incidence and mortality in Korea, 2017. Cancer Res Treat. 2017;49(2):306–12.
  Article PubMed PubMed Central Google Scholar
• Jung KW, Won YJ, Oh CM, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49(2):292–305.
  Article PubMed PubMed Central Google Scholar
• Burki TK. Unnecessary thyroid cancer screening in South Korea. Lancet Oncol. 2017;18(1):e6.
  Article PubMed Google Scholar
• Jegerlehner S, Bulliard JL, Aujesky D, et al. Overdiagnosis and overtreatment of thyroid cancer: a population-based temporal trend study. PLoS One. 2017;12(6):e0179387.
  Article PubMed PubMed Central Google Scholar
• Haymart MR, Esfandiari NH, Stang MT, Sosa JA. Controversies in the management of low-risk differentiated thyroid cancer. Endocr Rev. 2017;38(4):351–78.
  Article PubMed PubMed Central Google Scholar
• Molenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. J Clin Oncol. 2018;36(18):1831–9.
  Article CAS PubMed Google Scholar
• Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117(19):4439–46.
  Article PubMed Google Scholar
• Seo GH, Cho YY, Chung JH, Kim SW. Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: a nationwide, population-based study in Korea. Thyroid. 2015;25(8):927–34.
  Article PubMed Google Scholar
• Cho YY, Lim J, Oh CM, et al. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea. Cancer. 2015;121(2):259–68.
  Article PubMed Google Scholar
• Teng CJ, Hu YW, Chen SC, et al. Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: a nationwide population-based study. J Natl Cancer Inst. 2016;108(2).
• Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg. 2010;34(6):1192–202.
  Article PubMed Google Scholar
• Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.
  Article PubMed Google Scholar
• Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36–46.
  Article PubMed Google Scholar
• Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356:j477.
  Article PubMed PubMed Central Google Scholar
• Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer–viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–8.
  Article PubMed PubMed Central Google Scholar
• Shin HR, Won YJ, Jung KW, et al. Nationwide cancer incidence in Korea, 1999–2001; first result using the national cancer incidence database. Cancer Res Treat. 2005;37(6):325–31.
  Article PubMed PubMed Central Google Scholar
• Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for Optimal Use of HIRA Data. J Korean Med Sci. 2017;32(5):718–28.
  Article PubMed PubMed Central Google Scholar
• Shin JY, Roughead EE, Park BJ, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ. 2016;353:i2550.
  Article PubMed PubMed Central Google Scholar
• Park B, Sung J, Park K, Seo S, Kim S. Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database. 2003.
• Cho J, Choi YJ, Suh M, et al. Air pollution as a risk factor for depressive episode in patients with cardiovascular disease, diabetes mellitus, or asthma. J Affective Disorders. 2014;157:45–51.
  Article Google Scholar
• Kimm H, Yun JE, Lee SH, Jang Y, Jee SH. Validity of the diagnosis of acute myocardial infarction in korean national medical health insurance claims data: the korean heart study (1). Korean Circ J. 2012;42(1):10–5.
  Article PubMed PubMed Central Google Scholar
• Kim C, Jung SH, Kang DR, et al. Ambient particulate matter as a risk factor for suicide. Am J Psychiatry. 2010;167(9):1100–7.
  Article PubMed Google Scholar
• Oh H, Boo S. Burns in South Korea: an analysis of nationwide data from the health insurance review and assessment Service. Burns. 2016;42(3):675–81.
  Article PubMed Google Scholar
• Kim HS, Shin DW, Lee WC, Kim YT, Cho B. National Screening Program for Transitional Ages in Korea: a new screening for strengthening primary prevention and follow-up care. J Korean Med Sci. 2012;27:S70–5.
  Article PubMed PubMed Central Google Scholar
• Kim C, Bi X, Pan D, et al. The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid. 2013;23(5):575–82.
  Article PubMed PubMed Central Google Scholar
• Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science. 2017;355(6331):1330–4.
  Article CAS PubMed PubMed Central Google Scholar
• Mehta N, Hordines J, Volpe C, Doerr R, Cohen SA. Cellular effects of hypercholesterolemia in modulation of cancer growth and metastasis: a review of the evidence. Surgical oncology. 1997;6(3):179–85.
  Article CAS PubMed Google Scholar
• Arliss RM, Biermann CA. Do soy isoflavones lower cholesterol, inhibit atherosclerosis, and play a role in cancer prevention? Holistic Nursing Practice. 2002;17(1):40–8.
  Article Google Scholar
• Mutoh M, Akasu T, Takahashi M, et al. Possible involvement of hyperlipidemia in increasing risk of colorectal tumor development in human familial adenomatous polyposis. Jpn J Clin Oncol. 2006;36(3):166–71.
  Article PubMed Google Scholar
• Swinnen JV, Heemers H, van de Sande T, et al. Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol. 2004;92(4):273–9.
  Article CAS PubMed Google Scholar
• Kimura Y, Sumiyoshi M. High-fat, high-sucrose, and high-cholesterol diets accelerate tumor growth and metastasis in tumor-bearing mice. Nutr Cancer. 2007;59(2):207–16.
  Article CAS PubMed Google Scholar
• Brown M, Hart C, Tawadros T, et al. The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer. 2012;106(10):1689–96.
  Article CAS PubMed PubMed Central Google Scholar
• Yasuda Y, Shimizu M, Shirakami Y, et al. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci. 2010;101(7):1701–7.
  Article CAS PubMed Google Scholar
• Cruz P, Torres C, Ramirez ME, Epunan MJ, Valladares LE, Sierralta WD. Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol. Exp Ther Med. 2010;1(3):531–6.
  Article CAS PubMed PubMed Central Google Scholar
• Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control. 2011;22(11):1545–52.
  Article PubMed PubMed Central Google Scholar
• Oh HY, Lee EJ, Yoon S, Chung BH, Cho KS, Hong SJ. Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. Prostate. 2007;67(10):1061–9.
  Article CAS PubMed Google Scholar
• Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89(9):1638–44.
  Article CAS PubMed PubMed Central Google Scholar
• Subramanian S, Goldstein DP, Parlea L, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid. 2007;17(12):1277–88.
  Article PubMed Google Scholar
• Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family‐Cancer Database. Int J Ccancer. 2002;99(2):260-6.
• Zhang F, Xu L, Wei Q, Song X, Sturgis EM, Li G. Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma. Surgery. 2013;153(5):711–7.
  Article PubMed Google Scholar
• Duan X, Li J. Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis. Medicine. 2017;96(36).
• Do TN, Ucisik-Akkaya E, Davis CF, Morrison BA, Dorak MT. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet. 2009;195(1):31–6.
  Article CAS PubMed Google Scholar
• Cybulski C, Gorski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Gen. 2004;75(6):1131–5.
  Article CAS Google Scholar